10.06
price down icon2.33%   -0.24
 
loading
Schlusskurs vom Vortag:
$10.30
Offen:
$10
24-Stunden-Volumen:
7,532
Relative Volume:
0.29
Marktkapitalisierung:
$63.58M
Einnahmen:
$28.83M
Nettoeinkommen (Verlust:
$-13.34M
KGV:
-6.6184
EPS:
-1.52
Netto-Cashflow:
$-7.49M
1W Leistung:
-12.06%
1M Leistung:
-12.90%
6M Leistung:
+246.90%
1J Leistung:
+287.67%
1-Tages-Spanne:
Value
$9.99
$10.30
1-Wochen-Bereich:
Value
$9.99
$11.86
52-Wochen-Spanne:
Value
$1.44
$36.00

Exicure Inc Stock (XCUR) Company Profile

Name
Firmenname
Exicure Inc
Name
Telefon
847-673-1700
Name
Adresse
2430 N. HALSTED ST., CHICAGO, IL
Name
Mitarbeiter
7
Name
Twitter
@exicure
Name
Nächster Verdiensttermin
2024-08-12
Name
Neueste SEC-Einreichungen
Name
XCUR's Discussions on Twitter

Vergleichen Sie XCUR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
0.625 0 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.79 372.90M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
11.00 215.29M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
2.87 149.00M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1641 340.19M 2.07B -1.42B -1.37B -0.6765
 icon
MOBBW
Mobilicom Limited Warrants
0.3476 371.47M 0 0 0 0.00

Exicure Inc Stock (XCUR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-12-13 Herabstufung Chardan Capital Markets Buy → Neutral
2020-12-18 Eingeleitet BMO Capital Markets Outperform
2019-11-20 Eingeleitet Guggenheim Buy

Exicure Inc Aktie (XCUR) Neueste Nachrichten

pulisher
May 15, 2025

Exicure Delays 10-Q Filing Amid Acquisition - TipRanks

May 15, 2025
pulisher
May 08, 2025

(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com

May 08, 2025
pulisher
May 06, 2025

Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria

May 06, 2025
pulisher
May 06, 2025

Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks

May 06, 2025
pulisher
May 06, 2025

Exicure enters strategic convertible bond agreement - Investing.com

May 06, 2025
pulisher
May 06, 2025

Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance

May 06, 2025
pulisher
May 05, 2025

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire

May 05, 2025
pulisher
May 04, 2025

Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World

May 04, 2025
pulisher
May 04, 2025

Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World

May 04, 2025
pulisher
May 02, 2025

Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView

May 02, 2025
pulisher
Apr 30, 2025

Why Exicure Inc. (XCUR) Soared on Monday - MSN

Apr 30, 2025
pulisher
Apr 22, 2025

How To Trade (XCUR) - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey

Apr 21, 2025
pulisher
Apr 19, 2025

Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Exicure appoints new independent accounting firm By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 14, 2025

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace

Apr 14, 2025
pulisher
Apr 14, 2025

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Exicure appoints new independent accounting firm - Investing.com Australia

Apr 14, 2025
pulisher
Apr 11, 2025

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace

Apr 11, 2025
pulisher
Apr 06, 2025

How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 06, 2025

Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World

Apr 06, 2025
pulisher
Mar 30, 2025

Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest - The AM Reporter

Mar 30, 2025
pulisher
Mar 29, 2025

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK

Mar 27, 2025
pulisher
Mar 27, 2025

Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

HiTron Systems acquires $8.7 million in Exicure stock - Investing.com

Mar 26, 2025
pulisher
Mar 22, 2025

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire

Mar 22, 2025
pulisher
Mar 20, 2025

Exicure Inc Reports $9.7 Million Net Loss for Fiscal Year 2024 A - GuruFocus

Mar 20, 2025
pulisher
Mar 19, 2025

Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference - Business Wire

Mar 19, 2025
pulisher
Mar 19, 2025

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2% - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Exicure, Inc. Reports Full Year 2024 Financial Results - BioSpace

Mar 18, 2025
pulisher
Mar 18, 2025

EXICURE, INC. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before Important February 11 Deadline in Securities Class Action – XCUR - Business Wire

Mar 18, 2025
pulisher
Mar 17, 2025

Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval - Stocks Telegraph

Mar 17, 2025
pulisher
Mar 16, 2025

When (XCUR) Moves Investors should Listen - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 14, 2025

Exicure Gets Patent in Australia for Potential Cancer Treatment Combination -March 14, 2025 at 04:32 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 13, 2025

Exicure secures Australian patent for cancer treatment - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Exicure announces issuance of new patent in Australia - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Exicure secures Australian patent for cancer treatment By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire

Mar 13, 2025

Finanzdaten der Exicure Inc-Aktie (XCUR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Exicure Inc-Aktie (XCUR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
DGP Co., Ltd.
10% Owner
Sep 12 '24
Buy
3.00
237,223
711,669
849,223
$1.28
price down icon 1.54%
$30.93
price up icon 7.58%
$565.63
price up icon 0.69%
$3.99
price up icon 5.28%
$285.31
price up icon 0.67%
$71.31
price up icon 2.56%
Kapitalisierung:     |  Volumen (24h):